EuroBioHighTech 2025

An event fully dedicated to the Health technology Assessment for BioHighTech Innovation that will take place in the Urban Center of Trieste on the 25th September 2025.

Since 2016, EuroBioHighTech (EBHT) offers a very rich annual conference side, which had included so far four main sessions: Research, Education, Finance and Policy for Business Innovation in BioHighTech & AI. Already in the past editions, EBHT has proven to be a valuable opportunity of comparison and collaborations between local, national and international scientific institutes, universities, hospitals, large, small, medium-sized innovative enterprises and startups, that operates in Health sector in Friuli Venezia Giulia Region and in the Alpe Adria Area, encouraging them to work together or establishing new business collaborations, even with private and public finance support for developing BioHighTech innovation.

Attendance at previous EBHT editions has always been quite high, but above all, highly diverse, both in terms of remote participants and countries of origin, thanks to EBHT software platform. In the 2024 edition, we had approximately 60 participants locally at the Urban Center, and more than 500 people from over 20 European and non-EU countries connected to our SW platform.

This year’s tenth edition of EuroBioHighTech 2025 will focus in two round tables on the health clinical technology assessment carried out by public hospitals and/or other public and private institutions on the BioHighTech innovative pharmaceutical & medical technology of companies in the Friuli Venezia Giulia Region, Austria, Croatia and Slovenia and then in two other round tables in which will be discussed how much the private and public financing can contribute to encourage and support the growth of these innovative industrial BioHighTech sectors and to make the above mentioned innovative technologies available as soon as possible to patients with the European sharing of clinical HTA activities.

The EBHT Organizing Committee has decided to focus EuroBioHighTech 2025 on HTA following the recent entry into force in all European countries (January 12, 2025) of the relevant European Regulation on Health Technology Assessment - HTA (as provided for by the European Parliament and the Council on January 12, 2021, which amended Directive 2011/24/EU). According to this Regulation, the Clinical HTA activity will be progressively strengthened with the pooling at Central European level (Joint Clinical Assessment) of clinical data submitted on a pharmaceutical & medical technology in a single European country, to rapidly obtain a European Clinical Evaluation on the efficacy and safety of a new single pharmaceutical and medical technology, with systematic consultation (Joint Scientific Consultation) of patients and doctors, during the preparation of the HTA on the same pharmaceutical & technology, as well as the involvement of other stakeholders, or the early identification of emerging innovative technologies (Horizon Scanning). The Regulation entered into force on January 12, 2025, with the Clinical HTA of new cancer drugs and/or advanced therapy products. It will continue on January 13/01/2028, with the Clinical HTA of orphan drugs. By 01/2030, the EU Clinical HTA strategy for all other drugs will be completed. From 13/01/2026, however, high-risk medical devices will be selected for Clinical HTA procedures. Member states must take due account of European Joint Clinical Assessment (JCA) reports in their national HTAs and cannot re-request clinical data already submitted at EU level from developers.